New combo targets KRAS lung cancer in patients who Can't have surgery

NCT ID NCT07638878

Ongoing Disease control Sponsor: Guangzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial is testing a combination of the immunotherapy drug tislelizumab plus two chemotherapy drugs (albumin-bound paclitaxel and a platinum agent) in 30 people with a specific type of lung cancer called KRAS-mutant non-small cell lung cancer. The participants have advanced or metastatic cancer that cannot be removed with surgery. The main goal is to see how many patients' tumors shrink significantly after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab combined with albumin-bound paclitaxel and platinum chemotherapy
What this could lead to: If successful, this could offer a new treatment option for people with KRAS-mutated lung cancer who cannot have surgery, potentially shrinking tumors and extending survival.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not yet known if it works better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (LOCALLY ADVANCED OR METASTATIC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

combined small cell lung carcinoma lung cancer lung neoplasm Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER (LOCALLY ADVANCED OR METASTATIC)

Contacts and locations

Locations

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.